MSD’s investigational KRAS G12C inhibitor has shown signs of anti-tumour activity when used both alone and in combination ...

Shares of Verastem Oncology (VSTM) dropped 19% on Monday despite the company announcing positive updated data from the dose ...

KRAS mutations are among the most common genetic alterations in cancer and are considered particularly difficult to treat.

KRAS mutations are among the most common genetic alterations in cancer and are considered particularly difficult to treat. In ...

Here is a recap of every FDA approval announced by the regulatory agency in the month of May, spanning various cancer types.

Both ERAS-4001 and potential best-in-class pan-RAS molecular glue ERAS-0015 received IND clearance in May ahead of company guidance Initial Phase 1 monotherapy data for both RAS-targeting programs ...

DNA methylation, RTK pathway changes, and KRAS amplifications may drive resistance to sotorasib plus panitumumab in KRAS G12C ...

and will evaluate the safety and efficacy of VS-7375 in patients with advanced KRAS G12D mutant solid tumors. The starting dose for the Phase 1 study of 400 mg is based on the dose identified in ...

KRAS mutations are among the most common genetic alterations in cancer and are considered particularly difficult to treat. In ...

Researchers from The University of Texas MD Anderson Cancer Center have identified a new biomarker, TTF-1, that was predictive of survival outcomes for patients with advanced KRAS G12C-mutated non ...

I want my family to understand our shared cancer risks, but I sometimes struggle to face the painful reality of the disease ...

Lim, M.D., Erasca’s chairman, CEO, and co-founder. “ERAS-4001 targets multiple KRAS mutations as well as wildtype KRAS but spares HRAS and NRAS, potentially enabling a better therapeutic ...